Spero Therapeutics (SPRO) Change in Accured Expenses (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Change in Accured Expenses data on file, last reported at -$2.4 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 74.45% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 279.7% YoY) and the FY2025 annual result came in at -$12.1 million, down 208.77% from the prior year.
• Change in Accured Expenses fell to -$2.4 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.3 million in Q3 2024 to a low of -$9.5 million in Q1 2025.
• A 5-year average of -$659294.1 and a median of -$418000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 40033.33% in 2024, down 960.36% in 2024.
• Tracing SPRO's Change in Accured Expenses over 5 years: stood at $880000.0 in 2022, then tumbled by 100.68% to -$6000.0 in 2023, then surged by 40033.33% to $2.4 million in 2024, then sank by 193.11% to -$2.2 million in 2025, then dropped by 9.19% to -$2.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.4 million (Q1 2026), -$2.2 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.